Jazz Pharmaceuticals JAZZ and partner PharmaMar announced that they have initiated a phase III confirmatory study — LAGOON — to evaluate Zepzelca in patients with relapsed small cell lung cancer ...
Jazz Pharmaceuticals plc JAZZ announced that the first patient in a phase IIb study has been enrolled to evaluate its investigational drug suvecaltamide (JZP385) for the treatment of essential tremors ...
Zepzelca combo cuts the risk of disease progression or death by 46% and death by 27% vs. Tecentriq alone. Median PFS was 5.4 months with combo vs. 2.1 months with Tecentriq; OS was 13.2 vs. 10.6 ...
For the Utah Jazz, another regular season has nearly come and gone, as the Jazz wrap up their 2024-25 campaign with two games this weekend. As expected, it has been a year focused on player ...
June 20 (Reuters) - Jazz Pharmaceuticals (JAZZ.O), opens new tab said on Thursday its experimental drug to treat a common movement disorder failed to reduce tremor severity in a mid-stage study, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results